Volume 7, Issue 3 (11-2017)                   JABS 2017, 7(3): 353-360 | Back to browse issues page

XML Persian Abstract Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Afrakhteh M, zeinali M, Ghaffari M, Pourshohod A, Jamalan M. Investigating the Combination therapy effect of Trastuzumab and Idarubicin on growth inhibition of HER2-positive breast cancer cells line (SK-BR-3). JABS 2017; 7 (3) :353-360
URL: http://jabs.fums.ac.ir/article-1-1270-en.html
1- Department of Clinical Biochemistry, Cellular and Molecular Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
2- Biotechnology Research Center, Research Institute of Petroleum Industry (RIPI), Tehran, Iran , zeinalim@ripi.ir
3- Department of Clinical Biochemistry, Cellular and Molecular Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.Abadan School of Medical Sciences, Abadan, Iran
Abstract:   (5791 Views)

Background & Objectives: Trastuzumab and Idarubicin (4-methyl-daunorubicin) are two anti-neoplasmic agents that are widely used in cancer therapy. Idarubicin is more lipophilic than its parent drugs such as daunorubicin, therefore  it is absorbed more efficiently by the target cells. The main aim of this study was to Investigate the combinational effect of Trastuzumab (as anti-HER2 monoclonal antibody) and Idarubicin on growth inhibition of HER2 positive breast cancer cells.
Material & Methods: In this study, SK-BR-3 cell line as HER2-positive and MCF-7 as cell line with low-level of expression of HER2 were used for treatment process. After 72 hours incubation treatment with various concentrations of indicated agents, induced cytotoxicity of various concentrations of idarubicin, trastuzumab, and idarubicin-trastuzumab as combination was assessed by MTT assay.
Results: the results showed that Idarubicin discretely induced similar effect on both cell lines but trastuzumab as it expected induced its effect based on the level of HER2 expression and thus inhibited SK-BR-3 cell line growth in a more potent manner. Between all of treatment methods, idarubicin-trastuzumab therapy was the most efficient and specific treatment for the  reduction of cell viability of SK-BR-3 cells as HER2-positive cell line compared to CMF-7 cell line. Indicated combination therapy,  reduced viability of SK-BR-3 cells to 17% in comparison with  MCF-7 cell line  in similar conditions, and induced a significant (p≤0.01) SK-BR-3 cell death compared to  MCF-7 cells.
Conclusion: It seems that idarubicin combination therapy with trastuzumab in HER2-positive breast cancer cells can be used as an alternative effective treatment.
 

Full-Text [PDF 1180 kb]   (4034 Downloads)    
Type of Study: Research | Subject: Oncology
Received: 2016/10/30 | Accepted: 2017/05/24 | Published: 2017/11/26

Send email to the article author


Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2024 CC BY-NC 4.0 | Journal of Advanced Biomedical Sciences

Designed & Developed by: Yektaweb

Creative Commons License
This work is licensed under a Creative Commons — Attribution-NonCommercial 4.0 International (CC BY-NC 4.0)